The use of medicinal marijuana for posttraumatic stress disorder: A review of the current literature

Primary Care Companion to the Journal of Clinical Psychiatry

Volumn 17, Issue 3, 2015, Pages

  Yarnell, Stephanie ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABINOID 2 RECEPTOR; DRONABINOL; ENDOCANNABINOID; MEDICAL CANNABIS;

ANXIETY; AROUSAL; ARTICLE; CANNABIS ADDICTION; CANNABIS USE; COPING BEHAVIOR; DEPRESSION; DRUG EFFICACY; FOOD AND DRUG ADMINISTRATION; HUMAN; NEUROBIOLOGY; NONHUMAN; POSTTRAUMATIC STRESS DISORDER; SCORING SYSTEM; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; WITHDRAWAL SYNDROME;

EID: 84944342511     PISSN: 15235998     EISSN: 1555211X     Source Type: Journal    
DOI: 10.4088/PCC.15r01786     Document Type: Article

References (46)

1. Substance Abuse Mental Health Services Administration (SAMHSA). Results from the 2011 National Survey on Drug Use and Health: Summary of National Findings. Rockville, MD: US Department of Health and Human Services. http://www.samhsa.gov/data/sites/default/files/Revised2k11NSDUHSummNatFindings/ Revised2k11NSDUHSummNatFindings/NSDUHresults2011.htm. Updated September 2012. Accessed March 23, 2015.
2. Medical Marijuana Pros and Cons. 23 legal medical marijuana states and DC: laws, fees, and possession limits; 2014. ProCon.org Web site. http://medicalmarijuana.procon.org/view.resource.php?resourceID=000881. Updated January 8, 2015. Accessed August 25, 2014.
3. Volkow N. Marijuana and medicine: the need for a science-based approach. In: Stanford M, Avoy D, eds. Professional Perspectives on Addiction Medicine, Volume 2: Beyond Medical Marijuana: Toward Cannabinoid-Based Medicines. San Jose, CA: Santa Clara Valley Health & Hospital System, Department of Alcohol & Drug Services, Addiction Medicine and Therapy Program; 2009:24-28.
4. National Institutes of Health, Ad Hoc Group of Experts. Workshop on the medical utility of marijuana: report to the director. Paper presented at the National Institute of Health Conference; February 19-20, 1997; Bethesda, MD.
5. Watson SJ, Benson JA Jr, Joy JE. Marijuana and medicine: assessing the science base: a summary of the 1999 Institute of Medicine report. Arch Gen Psychiatry. 2000;57(6):547-552. PubMeddoi:10.1001/archpsyc.57.6.547.
6. Nunberg H, Kilmer B, Pacula RL, et al. An analysis of applicants presenting to a medical marijuana specialty practice in California. J Drug Policy Anal. 2011;4(1);pii:1. PubMed.
7. Bowles DW. Persons registered for medical marijuana in the United States. J Palliat Med. 2012;15(1):9-11. PubMed doi:10.1089/jpm.2011.0356.
8. Bonn-Miller MO, Vujanovic AA, Feldner MT, et al. Posttraumatic stress symptom severity predicts marijuana use coping motives among traumatic event-exposed marijuana users. J Trauma Stress. 2007;20(4):577-586. PubMed doi:10.1002/jts.20243.
9. Zvolensky MJ, Vujanovic AA, Bernstein A, et al. Marijuana use motives: a confirmatory test and evaluation among young adult marijuana users. Addict Behav. 2007;32(12):3122-3130. PubMeddoi:10.1016/j.addbeh.2007.06.010.
10. Johnson K, Mullin JL, Marshall EC, et al. Exploring the mediational role of coping motives for marijuana use in terms of the relation between anxiety sensitivity and marijuana dependence. Am J Addict. 2010;19(3):277-282. PubMed doi:10.1111/j.1521-0391.2010.00041.x.
11. Potter CM, Vujanovic AA, Marshall-Berenz EC, et al. Posttraumatic stress and marijuana use coping motives: the mediating role of distress tolerance. J Anxiety Disord. 2011;25(3):437-443. PubMeddoi:10.1016/j.janxdis.2010.11.007.
12. Cougle JR, Bonn-Miller MO, Vujanovic AA, et al. Posttraumatic stress disorder and cannabis use in a nationally representative sample. Psychol Addict Behav. 2011;25(3):554-558. PubMeddoi:10.1037/a0023076.
13. Cornelius JR, Kirisci L, Reynolds M, et al. PTSD contributes to teen and young adult cannabis use disorders. Addict Behav. 2010;35(2):91-94. PubMed doi:10.1016/j.addbeh.2009.09.007.
14. Bujarski SJ, Feldner MT, Lewis SF, et al. Marijuana use among traumatic event-exposed adolescents: posttraumatic stress symptom frequency predicts coping motivations for use. Addict Behav. 2012;37(1):53-59. PubMed doi:10.1016/j.addbeh.2011.08.009.
15. Greer GR, Grob CS, Halberstadt AL. PTSD symptom reports of patients evaluated for the New Mexico Medical Cannabis Program. J Psychoactive Drugs. 2014;46(1):73-77. PubMeddoi:10.1080/02791072.2013.873843.
16. Bonn-Miller MO, Boden MT, Bucossi MM, et al. Self-reported cannabis use characteristics, patterns and helpfulness among medical cannabis users. Am J Drug Alcohol Abuse. 2014;40(1):23-30.PubMed doi:10.3109/00952990.2013.821477.
17. Bremner JD, Southwick SM, Darnell A, et al. Chronic PTSD in Vietnam combat veterans: course of illness and substance abuse. Am J Psychiatry. 1996;153(3):369-375. PubMeddoi:10.1176/ajp.153.3.369.
18. Babson KA, Bonn-Miller M. Sleep disturbances: implications for cannabis use, cannabis use cessation, and cannabis use treatment. Current Addiction Reports. 2014;1(2):109-114. doi:10.1007/s40429-014-0016-9.
19. Bonn-Miller MO, Babson KA, Vandrey R. Using cannabis to help you sleep: heightened frequency of medical cannabis use among those with PTSD. Drug Alcohol Depend. 2014;136:162-165. PubMeddoi:10.1016/j.drugalcdep.2013.12.008.
20. Crippa JA, Zuardi AW, Martín-Santos R, et al. Cannabis and anxiety: a critical review of the evidence. Hum Psychopharmacol. 2009;24(7):515-523. PubMed doi:10.1002/hup.1048.
21. Calhoun PS, Sampson WS, Bosworth HB, et al. Drug use and validity of substance use self-reports in veterans seeking help for posttraumatic stress disorder. J Consult Clin Psychol. 2000;68(5):923-927. PubMed doi:10.1037/0022-006X.68.5.923.
22. Bonn-Miller MO, Harris AH, Trafton JA. Prevalence of cannabis use disorder diagnoses among veterans in 2002, 2008, and 2009. Psychol Serv. 2012;9(4):404-416. PubMed doi:10.1037/a0027622.
23. Bonn-Miller MO, Vujanovic AA, Drescher KD. Cannabis use among military veterans after residential treatment for posttraumatic stress disorder. Psychol Addict Behav. 2011;25(3):485-491. PubMeddoi:10.1037/a0021945.
24. Buckner JD, Heimberg RG, Schneier FR, et al. The relationship between cannabis use disorders and social anxiety disorder in the National Epidemiological Study of Alcohol and Related Conditions (NESARC). Drug Alcohol Depend. 2012;124(1-2):128-134. PubMed doi:10.1016/j.drugalcdep.2011.12.023.
25. Degenhardt L, Hall W, Lynskey M. Exploring the association between cannabis use and depression. Addiction. 2003;98(11):1493-1504. PubMed doi:10.1046/j.1360-0443.2003.00437.x.
26. Zvolensky MJ, Bernstein A, Sachs-Ericsson N, et al. Lifetime associations between cannabis, use, abuse, and dependence and panic attacks in a representative sample. J Psychiatr Res. 2006;40(6):477-486. PubMed doi:10.1016/j.jpsychires.2005.09.005.
27. Zvolensky MJ, Lewinsohn P, Bernstein A, et al. Prospective associations between cannabis use, abuse, and dependence and panic attacks and disorder. J Psychiatr Res. 2008;42(12):1017-1023.PubMed doi:10.1016/j.jpsychires.2007.10.012.
28. Kessler RC, Sonnega A, Bromet E, et al. Posttraumatic stress disorder in the National Comorbidity Survey. Arch Gen Psychiatry. 1995;52(12):1048-1060. PubMeddoi:10.1001/archpsyc.1995.03950240066012.
29. Stewart SH, Pihl RO, Conrod PJ, et al. Functional associations among trauma, PTSD, and substance-related disorders. Addict Behav. 1998;23(6):797-812. PubMed doi:10.1016/S0306-4603(98)00070-7.
30. Boden MT, Babson KA, Vujanovic AA, et al. Posttraumatic stress disorder and cannabis use characteristics among military veterans with cannabis dependence. Am J Addict. 2013;22(3):277-284.PubMed doi:10.1111/j.1521-0391.2012.12018.x.
31. Hoge CW, Castro CA, Messer SC, et al. Combat duty in Iraq and Afghanistan, mental health problems, and barriers to care. N Engl J Med. 2004;351(1):13-22. PubMed doi:10.1056/NEJMoa040603.
32. Institute of Medicine Committee on the Initial Assessment of Readjustment Needs of Military Personnel V. Returning Home from Iraq and Afghanistan: Preliminary Assessment of Readjustment Needs of Veterans, Service Members, and Their Families. Washington, DC: National Academies Press; 2010.
33. McFall ME, Mackay PW, Donovan DM. Combat-related posttraumatic stress disorder and severity of substance abuse in Vietnam veterans. J Stud Alcohol. 1992;53(4):357-363. PubMeddoi:10.15288/jsa.1992.53.357.
34. Reifman A, Windle M. Vietnam combat exposure and recent drug use: a national study. J Trauma Stress. 1996;9(3):557-568. PubMed doi:10.1002/jts.2490090311.
35. Rosen C, Greenbaum M, Fitt J. Demand for and utilization of VA outpatient mental health care for PTSD: 2001-2007. Poster presented at the Annual VA Health Services Research & Development Conference. February 13, 2008; Baltimore, MD.
36. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993;365(6441):61-65. PubMed doi:10.1038/365061a0.
37. Maximillian P. The endocannabinoid system. In: Stanford M, Avoy D, eds. Professional Perspectives on Addiction Medicine, Volume 2: Beyond Medical Marijuana: Toward Cannabinoid-Based Medicines. San Jose, CA: Santa Clara Valley Health & Hospital System Department of Alcohol & Drug Services Addiction Medicine and Therapy Program; 2009: 32-41.
38. Matsuda LA, Lolait SJ, Brownstein MJ, et al. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 1990;346(6284):561-564. PubMed doi:10.1038/346561a0.
39. Schwartz CE, Wright CI, Shin LM, et al. Differential amygdalar response to novel versus newly familiar neutral faces: a functional MRI probe developed for studying inhibited temperament. Biol Psychiatry. 2003;53(10):854-862. PubMed doi:10.1016/S0006-3223(02)01906-6.
40. Guggenhuber S, Monory K, Lutz B, et al. AAV vector-mediated overexpression of CB1 cannabinoid receptor in pyramidal neurons of the hippocampus protects against seizure-induced excitoxicity.PLoS ONE. 2010;5(12):e15707. PubMed doi:10.1371/journal.pone.0015707.
41. Marsicano G, Wotjak CT, Azad SC, et al. The endogenous cannabinoid system controls extinction of aversive memories. Nature. 2002;418(6897):530-534. PubMed doi:10.1038/nature00839.
42. Chhatwal JP, Davis M, Maguschak KA, et al. Enhancing cannabinoid neurotransmission augments the extinction of conditioned fear. Neuropsychopharmacology. 2005;30(3):516-524. PubMeddoi:10.1038/sj.npp.1300655.
43. Lutz B. The endocannabinoid system and extinction learning. Mol Neurobiol. 2007;36(1):92-101. PubMed doi:10.1007/s12035-007-8004-x.
44. Cermack T. Medical marijuana. In: Stanford M, Avoy D, eds. Professional Perspectives on Addiction Medicine, Volume 2: Beyond Medical Marijuana: Toward Cannabinoid-Based Medicines. San Jose, CA: Santa Clara Valley Health & Hospital System Department of Alcohol & Drug Services Addiction Medicine and Therapy Program; 2009:71.
45. Varvel SA, Wise LE, Niyuhire F, et al. Inhibition of fatty-acid amide hydrolase accelerates acquisition and extinction rates in a spatial memory task. Neuropsychopharmacology. 2007;32(5):1032-1041.PubMed doi:10.1038/sj.npp.1301224.
46. Rosin H. The return of pot. The New Republic. 1997;216(7):18-24.